Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions

Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop

(2013) Jane R. Kenny et al.   AAPS Journal

Drug-Drug Interaction Pattern Recognition

(2013) John Z. Duan   Drugs in research & development

The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics

(2012) Juan Jose Perez Ruixo et al.   AAPS Journal

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential

(2011) E. Kraynov et al.   DRUG METABOLISM AND DISPOSITION

Highlights From a Recent BIO Survey on Therapeutic Protein-Drug Interactions

(2011) et al.   JOURNAL OF CLINICAL PHARMACOLOGY

CYP-Mediated Therapeutic Protein-Drug Interactions

(2010) Jang-Ik Lee et al.   CLINICAL PHARMACOKINETICS

A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate

(2010) Chuanpu Hu et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis

(2009) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

(2009) Yaowei Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion

(2009) Hanna E. Silber et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Confirmatory analysis for phase III population pharmacokinetics

(2009) Chuanpu Hu et al.   PHARMACEUTICAL STATISTICS

Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis

(2008) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis

(2008) Chuanpu Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY